Global Advanced Liver Cancer Market, Global Advanced Liver Cancer Market Report, Global Advanced Liver Cancer Market Trends, Global Advanced Liver Cancer Market Size

Global Advanced Liver Cancer Market 2025–2029: Competitive Insights and Opportunities

November 26, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Advanced Liver Cancer Industry By The Forecast Year 2029?

The advanced liver cancer market size has experienced significant expansion in recent years. It is projected to increase from $1.89 billion in 2024 to $2.16 billion in 2025, achieving a compound annual growth rate (CAGR) of 14.5%. This historical growth can be attributed to factors such as increased awareness of liver cancer, a growing patient pool, rising demand for targeted therapies, an expanding healthcare infrastructure, and a greater preference for minimally invasive treatments.

The market for advanced liver cancer is anticipated to experience significant expansion in the coming years, projected to reach $3.74 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 14.7%. This expansion during the forecast period can be attributed to factors such as the rising incidence of liver cancer, increased healthcare expenditure, a growing prevalence of genetic conditions, wider adoption of precision medicine, and increased utilization of screening and diagnostic tests. Key developments expected during the forecast timeframe encompass the incorporation of artificial intelligence into treatment, the creation of novel drugs and therapies, an increase in research and development initiatives, advancements in targeted therapeutics, and a rising demand for personalized medicine.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20706&type=smp

Which Major Market Drivers Are Shaping The Future Of The Advanced Liver Cancer Market?

The increasing incidence of prolonged hepatitis infections is anticipated to boost the expansion of the advanced liver cancer market in the coming years. These infections are defined as persistent viral conditions lasting beyond six months, capable of leading to liver damage, cirrhosis, or liver cancer. A rise in such prolonged hepatitis infections stems from issues like insufficient screening, lack of vaccination, and late access to medical care. Specifically, chronic hepatitis B (HBV) or hepatitis C (HCV) infections are primary contributors to liver cirrhosis and hepatocellular carcinoma (HCC), which is the most prevalent type of liver cancer. Over time, these persistent viral infections can trigger liver inflammation, subsequent damage, and ultimately cancer. With the continued widespread presence of these infections, a greater number of individuals face the risk of developing advanced liver cancer. For example, data from April 2024, sourced from the World Health Organization, a Switzerland-based intergovernmental body, indicated that in 2022, chronic hepatitis B impacted 254 million people globally, with an annual report of 1.2 million new cases. Consequently, the growing occurrence of long-term hepatitis infections acts as a key driver for the expansion of the advanced liver cancer market.

How Is The Advanced Liver Cancer Market Segmented?

The advanced liver cancermarket covered in this report is segmented –

1) By Test Type: Imaging Test; Biopsy; Genomic Test; Other Test Types

2) By Technology: Fluorescent In Situ Hybridization; Next Generation Sequencing; Fluoroimmunoassay; Comparative Genomic Hybridization; Immunohistochemical; Other Technologies

3) By Distribution Channel: Direct Tenders; Retail Sales; Other Distribution Channel

4) By Application: Screening; Diagnostic And Predictive; Prognostic; Research

5) By End-User: Hospitals; Cancer Research Centers; Academic Institutes; Diagnostic Centers; Ambulatory Surgical Centers; Other End-Users

Subsegments:

1) By Imaging Test: Ultrasound; CT (Computed Tomography) Scan; MRI (Magnetic Resonance Imaging); PET (Positron Emission Tomography) Scan

2) By Biopsy: Needle Biopsy; Laparoscopic Biopsy; Surgical Biopsy

3) By Genomic Test: Next-Generation Sequencing (NGS); PCR (Polymerase Chain Reaction) Testing; Genetic Mutation Profiling

4) By Other Test Types: Serum Biomarker Testing; Liver Function Tests; Alpha-Fetoprotein (AFP) Test; Elastography Tests

What Are The Latest Industry Trends Transforming The Advanced Liver Cancer Market?

Major companies within the advanced liver cancer market are prioritizing the development of innovative medications, such as human monoclonal antibodies, to enhance treatment effectiveness and minimize adverse reactions for improved patient outcomes. A human monoclonal antibody is a laboratory-engineered molecule designed to replicate the immune system’s function in combating harmful pathogens or cancerous cells, specifically targeting antigens on their surface to trigger an immune response. For instance, in October 2022, AstraZeneca, a US-based pharmaceutical company, revealed that the US Food and Drug Administration (FDA) had granted approval for Imjudo (tremelimumab) when combined with Imfinzi (durvalumab), to treat adult patients afflicted with unresectable hepatocellular carcinoma (HCC), the most prevalent form of liver cancer. This authorization was supported by findings from the HIMALAYA Phase III trial, which indicated that this combination treatment decreased the risk of death by 22% compared to sorafenib, with approximately 31% of patients still alive after three years, contrasting with 20% for those receiving sorafenib. The treatment plan, referred to as STRIDE, involves a single administration of Imjudo followed by periodic doses of Imfinzi every four weeks, thereby presenting a novel therapeutic alternative for patients facing limited treatment avenues.

Which Major Firms Are Strengthening Their Position In The Advanced Liver Cancer Industry?

Major companies operating in the advanced liver cancer market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Stryker Corporation, Agilent Technologies Inc., Eisai Co. Ltd., Jiangsu Hengrui Pharmaceutical Co. Ltd, Exelixis Inc., Sirtex Medical Limited, Eureka Therapeutics, Abbisko Therapeutics Co. Ltd., Binhui Biopharmaceutical Co. Ltd., Tempest Therapeutics Inc., Auransa Inc., Mina Alpha Limited, Jennerex Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/advanced-liver-cancer–global-market-report

Which Region Currently Holds The Largest Share Of The Advanced Liver Cancer Market?

North America was the largest region in the advanced liver cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced liver cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Advanced Liver Cancer Market Report:

https://www.thebusinessresearchcompany.com/customise?id=20706&type=smp

Browse Through More Reports Similar to the Global Advanced Liver Cancer Market 2025, By The Business Research Company

Lung Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Lung Cancer Diagnostic And Screening Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Small Cell Lung Cancer Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/small-cell-lung-cancer-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795